Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race

  • Guggenheim Partners initiated coverage on Structure Therapeutics Inc GPCR with a Buy rating and a price target of $50 based on the multi-billion-dollar potential of oral small GLP1R agonist GSBR-1290. 
  • Suppose Phase 2a results in late 2023 demonstrate acceptable on-mechanism tolerability and at least 5% weight loss at 12 weeks in the obesity arm of the study. In that case, the analyst sees potential for ~2x return in the next 12-18 months, with a 4x return possible with robust Phase 2b data in 2025 and the GIPR/GLP1 oral co-agonist advancing into the clinic. 
  • Ultimately, the analyst sees positive GSBR-1290 results catalyzing a major partnership/collaboration with a large biopharma.
  • BMO Capital Markets has initiated coverage on Structure Therapeutics with a price target of $40 and an Outperform rating.
  • The analyst writes that the company's lead asset GSBR-1290 could be a competitive oral option in the growing obesity and type 2 diabetes market, with data coming in 4Q23. 
  • Injectable options dominate the market, but BMO's proprietary survey work suggests a strong desire for effective oral formulations.
  • The space has large players, including Eli Lilly And Co LLYPfizer Inc PFE, and Novo Nordisk A/S NVO.
  • GSBR-1290 could launch by 2027, well within the likely timeframe for launches of competitive assets.
  • BMO also notes the upside potential from follow-on assets in pulmonary and metabolic indications.
  • Price Action: GPCR shares are up 4.58% at $25.10 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetAnalyst RatingsGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!